InsiderTrades

Form 4 for RARE Ultragenyx Pharmaceutical Inc.

Accepted 2024-01-02 00:00:00 ET · period of report 2023-12-20 · accession 0001209191-24-000070 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-01-02 2024-01-02 RARE Huizenga Theodore Alan SVP, CAO M - OptEx $21.00 +3,000 27.9K +12% +$63.0K
D 2024-01-02 2023-12-20 RARE Huizenga Theodore Alan SVP, CAO A - Grant $0.00 +1,000 24.6K +4% $0
D 2024-01-02 2024-01-02 RARE Huizenga Theodore Alan SVP, CAO M - OptEx $0.00 -3,000 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-02 M A 3,000 $21.00 27,892 D — — (F3) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. (F2) Includes 278 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
2 Common Common Stock 2023-12-20 A A 1,000 $0.00 24,614 D — — (F1) Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
3 Derivative Stock Option (Right to Buy) 2024-01-02 M D 3,000 $0.00 0 D $21.00 · — to 2024-01-29 3,000 Common Stock (F4) 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.